News

Abbott Laboratories CEO Robert Ford unpacked his company’s latest quarterly report in a Thursday interview with CNBC’s Jim ...
Just a day after the S&P 500 and Nasdaq climbed into record territory, U.S. stocks end mixed, with American Express (AXP) and 3M (MMM) dragging the Dow, and more tariff drama muting markets.
Shares of Abbott Laboratories (NYSE:ABT) lost ~5% in the premarket on Thursday after the MedTech company provided its ...
"Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly ...
Investing.com -- Jefferies upgraded Abbott Laboratories (NYSE: ABT) to Buy from Hold, calling the market reaction to the ...
Discover Abbott Laboratories' Q2 2025 highlights: resilience drives high single-digit growth, double-digit EPS, and pipeline innovations.
Healthcare product and device company Abbott Laboratories (NYSE:ABT) will be announcing earnings results this Thursday ...
Abbott Laboratories’ Debt totaled $15 Bil at the end of the latest quarter, while its market capitalization stands at $233 ...
Abbott Laboratories (NYSE: ABT) is scheduled to announce Q2 earnings results on Thursday, July 17th, before market open.
ABT beats on Q2 earnings and revenues with double-digit growth in Medical Devices, yet shares fall 5% pre-market.
Abbott Laboratories stock tumbled Thursday after the maker of medical devices and nutrition products narrowed its full-year ...
Abbott Laboratories closed 6.52% below its 52-week high of $141.23, which the company reached on March 4th.